{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,7,30]],"date-time":"2025-07-30T16:09:02Z","timestamp":1753891742173,"version":"3.41.2"},"reference-count":25,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2020,12,22]],"date-time":"2020-12-22T00:00:00Z","timestamp":1608595200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100014468","name":"Mallinckrodt Pharmaceuticals","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100014468","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Neurol."],"abstract":"<jats:p><jats:bold>Background and Purpose:<\/jats:bold> Effective relapse treatment is critical for minimizing disability in patients with multiple sclerosis (MS). Repository corticotropin injection (RCI; Acthar\u00ae Gel) has demonstrated efficacy for the treatment of MS exacerbations. However, there is limited real-world evidence available regarding the relationship between the use of RCI for MS relapses and patient demographics, disease characteristics, and dosing regimens. In this multicenter, prospective, observational registry, patients receiving RCI for acute MS relapse were characterized, and recovery and safety outcomes were described.<\/jats:p><jats:p><jats:bold>Methods:<\/jats:bold> Patients were invited by their treating clinician to participate in the registry during a routine care visit. The decision to initiate RCI occurred before determination of study eligibility. All treatment decisions were made at the discretion of the patient's health care provider and were not mandated by the study design or protocol. Each enrolled patient was followed for up to 24 Months or until the date of study termination. The primary endpoint was the change from baseline in MS Impact Scale Version 1 (MSIS-29v1) physical subscale scores at Month 2. Additional assessments included the MSIS-29v1 psychological subscale, Expanded Disability Status Scale (EDSS), Clinical Global Impression of Improvement (CGI-I), Work Productivity and Activity Impairment Questionnaire: MS (WPAI:MS), and Health Resource Utilization (HRU) questionnaire.<\/jats:p><jats:p><jats:bold>Results:<\/jats:bold> Of 145 patients enrolled, 82 (56.6%) completed 24 Months of follow-up. Mean MSIS-29v1 physical subscale scores improved at 2 Months (\u22128.0; <jats:italic>P<\/jats:italic> = 0.0002) and 6 Months (\u22129.6; <jats:italic>P<\/jats:italic> &amp;lt; 0.0001). Mean MSIS-29v1 psychological subscale scores also improved at 2 Months (\u22127.9; <jats:italic>P<\/jats:italic> = 0.0040) and 6 Months (\u22129.9; <jats:italic>P<\/jats:italic> = 0.0012). Mean EDSS scores improved at 2 Months (\u22120.4; <jats:italic>P<\/jats:italic> &amp;lt; 0.0001) and 6 Months (\u22120.5; <jats:italic>P<\/jats:italic> &amp;lt; 0.0001). CGI-I scores indicated improvement in 63.4% of 71 patients at 2 Months and 61.4% of 57 patients at 6 Months (both <jats:italic>P<\/jats:italic> &amp;lt; 0.0001). Improvements on the WPAI:MS activity impairment domain (<jats:italic>P<\/jats:italic> &amp;lt; 0.001) and reductions in outpatient, specialist, and emergency department visits were observed at 2 and 6 Months. A total of 35 (28.0%) patients reported 83 adverse events; 11 (8.8%) patients reported 16 serious adverse events.<\/jats:p><jats:p><jats:bold>Conclusions:<\/jats:bold> This observational study found significant improvements in MS assessment scores after RCI treatment and supports the efficacy and tolerability of RCI for MS relapse.<\/jats:p><jats:p><jats:bold>Clinical Trial Registration:<\/jats:bold> This trial is registered on <jats:ext-link>ClinicalTrials.gov<\/jats:ext-link> with the identifier NCT02633033.<\/jats:p>","DOI":"10.3389\/fneur.2020.598496","type":"journal-article","created":{"date-parts":[[2020,12,22]],"date-time":"2020-12-22T06:01:40Z","timestamp":1608616900000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":7,"title":["A Prospective Observational Registry of Repository Corticotropin Injection (Acthar\u00ae Gel) for the Treatment of Multiple Sclerosis Relapse"],"prefix":"10.3389","volume":"11","author":[{"given":"Jeffrey","family":"Kaplan","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tamara","family":"Miller","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Matthew","family":"Baker","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Bryan","family":"Due","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Enxu","family":"Zhao","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1965","published-online":{"date-parts":[[2020,12,22]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"234","DOI":"10.1016\/j.msard.2015.03.005","article-title":"Impact of multiple sclerosis relapse: the NARCOMS participant perspective","volume":"4","author":"Nickerson","year":"2015","journal-title":"Mult Scler Relat Disord."},{"key":"B2","doi-asserted-by":"publisher","first-page":"470476","DOI":"10.1155\/2013\/470476","article-title":"Assessing relapse in multiple sclerosis questionnaire: results of a pilot study","volume":"2013","author":"Perrin Ross","year":"2013","journal-title":"Mult Scler Int."},{"key":"B3","doi-asserted-by":"publisher","first-page":"199","DOI":"10.1159\/000382130","article-title":"Multiple sclerosis relapses: epidemiology, outcomes and management. A systematic review","volume":"44","author":"Kalincik","year":"2015","journal-title":"Neuroepidemiology."},{"key":"B4","doi-asserted-by":"publisher","first-page":"97","DOI":"10.1007\/s13311-012-0160-7","article-title":"Treatment of acute relapses in multiple sclerosis","volume":"10","author":"Berkovich","year":"2013","journal-title":"Neurotherapeutics."},{"volume-title":"Acthar Gel [package insert]","year":"2019","key":"B5"},{"key":"B6","doi-asserted-by":"publisher","first-page":"969","DOI":"10.1212\/WNL.39.7.969","article-title":"Relative efficacy of intravenous methylprednisolone and ACTH in the treatment of acute relapse in MS","volume":"39","author":"Thompson","year":"1989","journal-title":"Neurology."},{"key":"B7","doi-asserted-by":"publisher","first-page":"66","DOI":"10.7224\/1537-2073-14.S2.1","article-title":"Adrenocorticotropic hormone treatment of multiple sclerosis exacerbations","volume":"14","author":"Berkovich","year":"2012","journal-title":"Int J MS Care."},{"key":"B8","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1080\/10799893.2020.1818094","article-title":"Distinct binding and signaling activity of Acthar Gel compared to other melanocortin receptor agonists","author":"Huang","year":"2020","journal-title":"J Recept Signal Transd."},{"key":"B9","doi-asserted-by":"publisher","first-page":"A25","DOI":"10.1053\/j.ajkd.2013.02.044","article-title":"Plasma cortisol levels after natural ACTH 1-39 and synthetic ACTH 1-24 in humans [NKF abstract 39]","volume":"61","author":"Berg","year":"2013","journal-title":"Am J Kidney Dis."},{"key":"B10","doi-asserted-by":"publisher","first-page":"83","DOI":"10.1177\/1756285613518599","article-title":"Mechanisms of action of ACTH in the management of relapsing forms of multiple sclerosis","volume":"7","author":"Berkovich","year":"2014","journal-title":"Ther Adv Neurol Disord."},{"key":"B11","doi-asserted-by":"publisher","first-page":"130","DOI":"10.1177\/1352458512458844","article-title":"Mechanisms of action of adrenocorticotropic hormone and other melanocortins relevant to the clinical management of patients with multiple sclerosis","volume":"19","author":"Arnason","year":"2013","journal-title":"Mult Scler."},{"key":"B12","doi-asserted-by":"publisher","first-page":"300","DOI":"10.1186\/s13075-015-0823-y","article-title":"Direct effects of HP Acthar Gel on human B lymphocyte activation in vitro","volume":"17","author":"Olsen","year":"2015","journal-title":"Arthritis Res Ther."},{"key":"B13","doi-asserted-by":"publisher","first-page":"777","DOI":"10.26226\/morressier.59a3e8b5d462b8028d894978","article-title":"Melanocortin receptor mediated anti-inflammatory effect of repository corticotropin injection on human monocyte-derived macrophages [ECTRIMS-ACTRIMS abstract EP1481]","volume":"23","author":"Healy","year":"2017","journal-title":"Mult Scler J."},{"key":"B14","doi-asserted-by":"publisher","first-page":"962","DOI":"10.1093\/brain\/124.5.962","article-title":"The Multiple Sclerosis Impact Scale (MSIS-29): a new patient-based outcome measure","volume":"124","author":"Hobart","year":"2001","journal-title":"Brain."},{"key":"B15","doi-asserted-by":"publisher","first-page":"1444","DOI":"10.1212\/WNL.33.11.1444","article-title":"Rating neurologic impairment in multiple sclerosis: an expanded disability status scale (EDSS)","volume":"33","author":"Kurtzke","year":"1983","journal-title":"Neurology."},{"key":"B16","first-page":"28","article-title":"The clinical global impressions scale: applying a research tool in clinical practice","volume":"4","author":"Busner","year":"2007","journal-title":"Psychiatry."},{"key":"B17","doi-asserted-by":"publisher","first-page":"353","DOI":"10.2165\/00019053-199304050-00006","article-title":"The validity and reproducibility of a work productivity and activity impairment instrument","volume":"4","author":"Reilly","year":"1993","journal-title":"Pharmacoeconomics."},{"key":"B18","doi-asserted-by":"publisher","first-page":"413","DOI":"10.1191\/1352458504ms1068oa","article-title":"Clinical impact of intravenous methylprednisolone in attacks of multiple sclerosis","volume":"10","author":"Nos","year":"2004","journal-title":"Mult Scler."},{"key":"B19","doi-asserted-by":"publisher","first-page":"529","DOI":"10.1212\/WNL.51.2.529","article-title":"Double-blind, randomized, placebo-controlled study of oral, high-dose methylprednisolone in attacks of MS","volume":"51","author":"Sellebjerg","year":"1998","journal-title":"Neurology."},{"key":"B20","doi-asserted-by":"publisher","first-page":"511","DOI":"10.1136\/jnnp.50.5.511","article-title":"A double-blind controlled trial of high dose methylprednisolone in patients with multiple sclerosis: 1. Clinical effects","volume":"50","author":"Milligan","year":"1987","journal-title":"J Neurol Neurosurg Psychiatry."},{"key":"B21","doi-asserted-by":"publisher","first-page":"147","DOI":"10.1016\/S0022-510X(97)00159-7","article-title":"The effects of high-dose intravenous methylprednisolone on event-related potentials in patients with multiple sclerosis","volume":"152","author":"Filipovi\u0107","year":"1997","journal-title":"J Neurol Sci."},{"key":"B22","doi-asserted-by":"publisher","first-page":"157","DOI":"10.1136\/jnnp.48.2.157","article-title":"Intravenous methylprednisolone for multiple sclerosis in relapse","volume":"48","author":"Barnes","year":"1985","journal-title":"J Neurol Neurosurg Psychiatry."},{"key":"B23","doi-asserted-by":"publisher","first-page":"485","DOI":"10.1177\/1352458507084650","article-title":"Factors predicting incomplete recovery from relapses in multiple sclerosis: a prospective study","volume":"14","author":"Leone","year":"2008","journal-title":"Mult Scler."},{"key":"B24","doi-asserted-by":"publisher","first-page":"e0120829","DOI":"10.1371\/journal.pone.0120829","article-title":"A predictive model for corticosteroid response in individual patients with MS relapses","volume":"10","author":"Rakusa","year":"2015","journal-title":"PLoS ONE."},{"key":"B25","doi-asserted-by":"publisher","first-page":"189","DOI":"10.1177\/1756285615618642","article-title":"Clinical experience with repository corticotropin injection in patients with multiple sclerosis experiencing mood changes with intravenous methylprednisolone: a case series","volume":"9","author":"Murray","year":"2016","journal-title":"Ther Adv Neurol Disord."}],"container-title":["Frontiers in Neurology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fneur.2020.598496\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,12,22]],"date-time":"2020-12-22T06:01:43Z","timestamp":1608616903000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fneur.2020.598496\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,12,22]]},"references-count":25,"alternative-id":["10.3389\/fneur.2020.598496"],"URL":"https:\/\/doi.org\/10.3389\/fneur.2020.598496","relation":{},"ISSN":["1664-2295"],"issn-type":[{"type":"electronic","value":"1664-2295"}],"subject":[],"published":{"date-parts":[[2020,12,22]]},"article-number":"598496"}}